Eleven Biotherapeutics Priced, Nasdaq: EBIO
Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.
Industry: Health Care
First Day Return: +8.5%
Industry: Health Care
EBIO
Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.
| IPO Data | |
|---|---|
| IPO File Date | 12/30/2013 |
| Offer Price | $10.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 5.0 |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/05/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2008 |
| Employees at IPO | 16 |
| Website www.elevenbio.com | |
IPO News for Eleven Biotherapeutics
Eleven Biotherapeutics (EBIO) Performance
